Bigeminy recombinant subunit vaccine for avian influenza and avian infectious bronchitis as well as preparation method and application of bigeminy recombinant subunit vaccine
By constructing a recombinant protein to replace the head domain of the HA protein of avian influenza virus with the receptor-binding domain of the S protein of avian infectious bronchitis virus, a bivalent recombinant subunit vaccine was prepared. This solved the problem of antigen drift in existing vaccines and achieved effective prevention and cross-protection against H9N2 subtype avian influenza and QX subtype avian infectious bronchitis.
Patent Information
- Application Number
- CN202511892590.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-16
- Publication Date
- 2026-01-16
- Estimated Expiration
- 2045-12-16
AI Technical Summary
Existing vaccines suffer from reduced protective efficacy and difficulty in controlling virus transmission due to antigenic drift when preventing H9N2 subtype avian influenza and QX subtype avian infectious bronchitis virus, and there is a lack of effective bivalent vaccine solutions.
A recombinant protein was constructed by replacing the head domain of the HA protein of avian influenza virus with the receptor-binding domain of the S protein of avian infectious bronchitis virus, and adding GCN4 and Trimer-tag tags. The expression efficiency was improved by utilizing the GP64 signal peptide sequence of baculovirus, and a bivalent recombinant subunit vaccine was prepared.
This vaccine can induce high levels of neutralizing and specific antibodies, effectively reducing viral shedding and tissue viral load after viral infection. It has good immunogenicity and cross-protection effects, and can simultaneously prevent H9N2 subtype avian influenza and QX subtype avian infectious bronchitis.
Smart Images

Figure CN121343012A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application belongs to the technical field of vaccines, and particularly relates to a bivalent recombinant subunit vaccine for avian influenza and avian infectious bronchitis and a preparation method and application thereof. BACKGROUND
[0002] H9N2 subtype avian influenza virus (AIV) is one of the low pathogenic influenza viruses widely prevalent in poultry around the world. H9N2 virus mainly infects chickens, ducks, turkeys and pigeons, etc. In the early stage of infection, it usually shows mild respiratory symptoms such as cough, sneezing, nasal discharge, and decreased egg production, etc., with low mortality. However, in the case of mixed infection with bacteria or other viruses, such as Escherichia coli, mycoplasma, H5 or H7 subtype virus, H9N2 infection can significantly aggravate the condition of poultry, leading to increased mortality and causing huge economic losses to the poultry industry. In addition, H9N2 virus can cause latent infection in poultry and exist for a long time, with a long virus shedding time, making it difficult to eliminate the virus and exacerbating environmental pollution and transmission risk. Genetic analysis shows that H9N2 virus has high genetic diversity, and there are obvious differences in hemagglutinin (HA) and neuraminidase (NA) proteins between strains prevalent in different places. The virus accumulates mutations through antigenic drift, leading to decreased protection efficacy of existing vaccines and posing challenges to prevention and control.
[0003] HA protein is one of the two surface glycoproteins encoded by avian influenza virus, which is a typical type I transmembrane protein. HA protein is a trimeric rod-shaped molecule, which is assembled into a glycoprotein form in the host cell, and then directed to the cell surface through the Golgi network. Host proteases can cleave the precursor HA (HA0) into two subunits: HA1 and HA2. Among them, HA1 is mainly responsible for binding to the host cell sialic acid (SA) receptor, while HA2 serves as a transmembrane subunit to mediate the fusion of the viral membrane with the endosome membrane after AIV is internalized. HA protein is the main recognition target of host acquired immune response. After AIV infects the host, it will trigger a strong immune response and induce the production of a large amount of neutralizing antibodies. Therefore, HA protein is the main target antigen for the development of influenza virus vaccine. Under the immune pressure of the body, HA protein also undergoes continuous variation, and the main site of antigenic variation is located in the head domain of HA protein on the surface, while the stem domain of HA protein is relatively conserved, so the stem domain of HA protein is also often used by researchers to develop a broad-spectrum vaccine for AIV.
[0004] QX subtype avian infectious bronchitis virus (IBV) is one of the important pathogens causing respiratory diseases in poultry, which belongs to the family of Coronaviridae and the genus of gamma-coronavirus. Compared with classic M41, Mass and other strains, QX subtype avian infectious bronchitis virus shows higher transmission, more extensive tissue tropism and more complex clinical symptoms. QX subtype avian infectious bronchitis virus mainly spreads through the respiratory tract, causing typical respiratory symptoms such as respiratory difficulty, cough, and increased nasal secretion in poultry. In addition to respiratory lesions, QX strains have obvious urogenital system invasion characteristics, which can cause kidney enlargement, pallor, urate deposition, and so-called "kidney type" performance in clinic. At the same time, when infecting layers, the virus can cause oviduct dysplasia, the appearance of pseudo-male, the decline of egg production and the deterioration of eggshell quality, which seriously affects the production performance of layers. In addition, infection of QX subtype avian infectious bronchitis virus in the broiler stage often causes high morbidity and mortality, which brings significant economic losses to the poultry industry.
[0005] S protein is the most important structural protein on the surface of avian infectious bronchitis virus, which mainly mediates the binding of virus and host cells and membrane fusion. S protein is composed of S1 and S2 subunits, wherein S1 subunit is responsible for recognizing host cell receptors, determining the tissue tropism and immunogenicity of virus, and is a key target for vaccine design and variation monitoring. The S1 subunit contains a receptor binding domain RBD, which can specifically bind to the glycosyl receptor on the surface of host cells to initiate the virus invasion process. The RBD region is usually located at the N-terminal to the middle of the S1 subunit, and the structure is highly variable, with obvious differences in RBD sequences among different IBV genotypes, which is an important reason for the poor cross-protection among different serotypes. The S2 subunit is mainly responsible for the membrane fusion process and is relatively conservative.
[0006] H9N2 subtype avian influenza virus and QX subtype avian infectious bronchitis virus are two viruses that currently pose a serious threat to the global poultry industry, so it is of great significance to design a low-cost bivalent vaccine that can prevent both viruses. SUMMARY
[0007] The purpose of the present application is to provide an avian influenza and avian infectious bronchitis bivalent recombinant subunit vaccine and a preparation method and application thereof.
[0008] The purpose of the present application can be achieved by the following technical solutions:
[0009] In a first aspect, the present application claims a recombinant protein, which is a chimeric protein constructed by replacing the head domain of hemagglutinin (HA) protein of avian influenza virus (AIV) with the receptor binding domain (RBD) of S protein of avian infectious bronchitis virus (IBV).
[0010] Further, the RBD domain of S protein of avian infectious bronchitis virus is derived from CK / CH / JS / CZ211063 strain of QX subtype avian infectious bronchitis virus, and the head domain of HA protein of avian influenza virus is derived from A / chicken / Anhui / LH99 / 2017 strain of H9N2 subtype avian influenza virus.
[0011] Further, the 61st to 285th amino acids of SEQ ID NO: 2 of HA1 subunit of HA protein of avian influenza virus are replaced with the 21st to 277th amino acids of SEQ ID NO: 1 of S protein of avian infectious bronchitis virus, and the two sequences are connected by a GGGG linker peptide.
[0012] Further, the signal peptide of the recombinant protein is replaced with the signal peptide amino acid sequence of baculovirus GP64 protein shown in SEQ ID NO: 3 to replace the signal peptide sequence of the original avian influenza virus HA protein shown in SEQ ID NO: 4.
[0013] Further, the recombinant protein further comprises a tag protein for promoting trimer structure and facilitating purification; preferably, the tag protein is GCN4 tag, Trimer-tag tag and histidine (His) tag. Further, the 414th to 427th amino acid sequence of SEQ ID NO: 5 of the avian influenza virus HA protein is replaced with the GCN4 tag sequence.
[0014] Most preferably, the amino acid sequence of the recombinant protein is shown in SEQ ID NO: 6.
[0015] In a second aspect, the present application claims a nucleic acid molecule encoding the above-mentioned recombinant protein, and the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO: 7.
[0016] In a third aspect, the present application claims a biological material comprising the above-mentioned nucleic acid molecule, and the biological material is an expression cassette, a recombinant vector or a recombinant microorganism.
[0017] In a fourth aspect, the present application claims a preparation method of the above-mentioned recombinant protein, and the method comprises the following steps:
[0018] (1) Gene cloning: homologous recombination primers shown as SEQ ID NO: 8 and SEQ ID NO: 9 are designed according to the nucleotide sequence of the recombinant protein and pFastbacHT B vector, PCR amplification is carried out, and the amplification product is connected with the linearized pFastbacHTB vector, transformed to obtain a recombinant transfer vector;
[0019] (2) Recombinant bacmid preparation: the recombinant transfer vector is transformed into DH10Bac E. coli competent cells to obtain a recombinant bacmid;
[0020] (3) Virus rescue and amplification: the recombinant bacmid is used to transfect insect cells, a recombinant baculovirus is rescued, and is amplified and titrated;
[0021] (4) Protein expression: the insect cells are infected with the amplified recombinant baculovirus, and the cells are harvested 96 hours after infection;
[0022] (5) Protein purification: the harvested cells are lysed, concentrated by centrifugation, and purified by using a nickel ion affinity chromatography column to obtain the recombinant protein.
[0023] In the above method, the insect cells are Sf9 cells.
[0024] In a fifth aspect, the present application claims to protect a vaccine comprising the recombinant protein as described above as an immunogenic component, and a pharmaceutically acceptable adjuvant.
[0025] In a sixth aspect, the present application claims to protect the use of the recombinant protein as described above in the preparation of a vaccine or a drug for preventing H9N2 subtype avian influenza and QX subtype avian infectious bronchitis of poultry.
[0026] In a seventh aspect, the present application claims to protect the use of the vaccine as described above in the preparation of a drug for preventing H9N2 subtype avian influenza and QX subtype avian infectious bronchitis of poultry.
[0027] In the technical scheme of the present application, the vaccine can induce the production of high-level neutralizing antibodies against homologous and heterologous H9N2 subtype AIV; induce the production of high-level specific antibodies and neutralizing antibodies against QX subtype IBV; effectively reduce the virus discharge amount, tissue virus load after virus infection and alleviate pathological damage.
[0028] The present application is based on the characteristics that both the avian influenza virus HA protein and the avian infectious bronchitis virus S protein have a large number of antigen epitopes and form a trimer, and the head domain of the avian influenza virus HA protein is replaced with the RBD domain of the avian infectious bronchitis virus S protein. In order to ensure the formation of a trimer structure, GCN4 and Trimer-tag trimer tags are added; in order to increase the expression of the recombinant protein in insect cells, the signal peptide sequence of the avian influenza virus HA protein is replaced with the signal peptide sequence of the baculovirus GP64 protein. The expressed recombinant protein has a stable trimer structure. A bivalent recombinant subunit vaccine is prepared using the recombinant protein, and the bivalent recombinant subunit vaccine has good immunogenicity, can produce high levels of neutralizing antibodies against homologous and heterologous H9N2 subtype avian influenza viruses, has a cross-protection effect; and can also induce high levels of specific antibodies and neutralizing antibodies against QX subtype avian infectious bronchitis virus, effectively inhibit virus shedding and viral load, and reduce tissue lesions.
[0029] Advantages of the present application
[0030] The bivalent recombinant subunit vaccine constructed by the present application has good immunogenicity, has a cross-protection effect on H9N2 subtype avian influenza, can simultaneously prevent H9N2 subtype avian influenza and QX subtype avian infectious bronchitis, and can reduce the prevention and control pressure of the two viruses, thereby laying a foundation for the development and industrialized production of a new bivalent vaccine. BRIEF DESCRIPTION OF DRAWINGS
[0031] Figure 1 is the design and construction strategy of the corresponding recombinant protein of the bivalent recombinant subunit vaccine of avian influenza virus and avian infectious bronchitis virus.
[0032] Figure 2 is the three-dimensional structure prediction of the recombinant protein by AlphaFold3.
[0033] Figure 3 is the PCR identification result of the recombinant bacmid.
[0034] Figure 4 is the expression verification of the recombinant protein in insect cells and the exploration of the optimal expression conditions by Western blot.
[0035] Figure 5 is the purification effect of the recombinant protein by nickel ion chromatography column identified by SDS-PAGE.
[0036] Figure 6 is the ultraviolet absorption graph of the recombinant protein identified by Superdex200 molecular sieve chromatography, and the non-denaturing gel electrophoresis identification of the elution peak, and the transmission electron microscope observation.
[0037] Figure 7The immunization strategy of the bivalent recombinant subunit vaccine and the challenge strategy of H9N2 subtype avian influenza virus.
[0038] Figure 8 The neutralizing antibody level against H9N2 subtype avian influenza virus induced after immunization with the bivalent recombinant subunit vaccine. A is the neutralizing antibody level against homologous H9N2 subtype avian influenza virus induced by the bivalent recombinant subunit vaccine. Significant difference analysis: *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. B is the neutralizing antibody level against heterologous H9N2 subtype avian influenza virus induced by the bivalent recombinant subunit vaccine. Significant difference analysis: *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
[0039] Figure 9 The virus shedding of immunized chickens after challenge with homologous H9N2 subtype avian influenza virus. A is the throat virus shedding of immunized chickens after challenge with homologous H9N2 subtype avian influenza virus. B is the cloaca virus shedding of immunized chickens after challenge with homologous H9N2 subtype avian influenza virus.
[0040] Figure 10 The virus shedding of immunized chickens after challenge with heterologous H9N2 subtype avian influenza virus. A is the throat virus shedding of immunized chickens after challenge with heterologous H9N2 subtype avian influenza virus. B is the cloaca virus shedding of immunized chickens after challenge with heterologous H9N2 subtype avian influenza virus.
[0041] Figure 11 The pathological changes of trachea and lung of immunized chickens after challenge with homologous H9N2 subtype avian influenza virus.
[0042] Figure 12 The pathological changes of trachea and lung of immunized chickens after challenge with heterologous H9N2 subtype avian influenza virus.
[0043] Figure 13 The immunization strategy of the bivalent recombinant subunit vaccine and the challenge strategy of QX subtype avian infectious bronchitis virus.
[0044] Figure 14 The specific antibody level against QX subtype avian infectious bronchitis virus induced by the bivalent recombinant subunit vaccine. Significant difference analysis: *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.
[0045] Figure 15The figure is the level of neutralizing antibody against QX subtype avian infectious bronchitis virus induced by the bivalent recombinant subunit vaccine. Significant difference analysis: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
[0046] Figure 16 The figure is the virus shedding of the immunized chickens after QX subtype avian infectious bronchitis virus challenge. A is the throat virus shedding of the immunized chickens after QX subtype avian infectious bronchitis virus challenge. Significant difference analysis: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. B is the cloaca virus shedding of the immunized chickens after QX subtype avian infectious bronchitis virus challenge. Significant difference analysis: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
[0047] Figure 17 The figure is the tracheal cilia score of the immunized chickens after QX subtype avian infectious bronchitis virus challenge.
[0048] Figure 18 The figure is the tissue virus load of the immunized chickens after QX subtype avian infectious bronchitis virus challenge. A is the virus load level in the trachea of the immunized chickens after QX subtype avian infectious bronchitis virus challenge. Significant difference analysis: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. B is the virus load level in the lung of the immunized chickens after QX subtype avian infectious bronchitis virus challenge. Significant difference analysis: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. C is the virus load level in the kidney of the immunized chickens after QX subtype avian infectious bronchitis virus challenge. Significant difference analysis: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
[0049] Figure 19 The figure is the pathological changes of the trachea, lung and kidney of the immunized chickens after QX subtype avian infectious bronchitis virus challenge. DETAILED DESCRIPTION
[0050] The application will be further described below in conjunction with specific examples and drawings. Unless otherwise specified, the experimental methods described in the application are conventional methods; the biological materials described can be obtained from commercial channels.
[0051] Example 1: Design and construction strategy of recombinant protein
[0052] In the sequence design of the recombinant protein, the RBD domain is derived from the 21-277 amino acid residues of the QX subtype IBV strain CK / CH / JS / CZ211063S protein (SEQ ID NO: 1), and the RBD domain is used to replace the 61-285 amino acid residues of the H9N2 subtype AIV strain A / chicken / Anhui / LH99 / 2017 HA protein (SEQ ID NO: 2), and the two fragments are connected by a GGGG linker.
[0053] The 414-427 amino acid sequence of the avian influenza virus HA protein shown as SEQ ID NO: 5 is replaced with the GCN4 sequence (CMKQIEDKIEEIESK), and a trimer tag (YIPEAPRDGQAYVRKDGEWVLLSTFL) is added at the C-terminal of the HA2 subunit to facilitate the formation of a trimer structure after protein folding. In addition, the signal peptide sequence of the HA protein (SEQ ID NO: 4) is replaced with the baculovirus membrane protein GP64 signal peptide (SEQ ID NO: 3) to increase the expression efficiency of the protein in insect cells. Finally, a 6×His tag is added at the C-terminal of the sequence to construct the recombinant protein (amino acid sequence as SEQ ID NO: 6, nucleic acid sequence as SEQ ID NO: 7), as shown in Figure 1 and Figure 2 .
[0054] The amino acid sequence of the H9N2 subtype AIV strain A / chicken / Anhui / LH99 / 2017 HA protein is shown as SEQ ID NO: 12.
[0055] Example 2: Construction of recombinant transfer vector
[0056] According to the nucleotide sequence of the recombinant protein coding gene SEQ ID NO: 7 and the sequence of the pFastbacHT B vector, homologous recombination primers are designed, the upstream primer sequence is shown as SEQ ID NO: 8, and the downstream primer sequence is shown as SEQ ID NO: 9.
[0057] PCR amplification is performed using the upstream and downstream primer sequences of the recombinant protein coding gene, and the PCR reaction system is as follows: Phanta Max Super Fidelity DNA polymerase 1 μL, 2×Phanta Max Buffer 25 μL, dNTP Mix 1 μL, 1 μL of each of the upstream and downstream primers, 1 μL of diluted template, and ddH2O to make up to 50 μL. The template for PCR amplification is a recombinant plasmid obtained by constructing the nucleotide sequence of the recombinant protein coding gene on the pUC19 vector by a biological company.
[0058] Reaction conditions: 95 ℃ pre-denaturation for 5 min; 95 ℃ denaturation for 30 s, 55 ℃ annealing for 30 s, 72 ℃ extension for 2 min, 35 cycles; 72 ℃ total extension for 10 min.
[0059] The PCR product was identified by 1% agarose gel electrophoresis, and the gel with the correct size of the gene fragment was cut off to recover the target gene fragment. The recovered target fragment was ligated with the double-digested pFastbacHT B vector.
[0060] The ligation product was transformed into DH5a competent cells. The plasmid was extracted in a small amount by a conventional method, and sequenced after preliminary identification by electrophoresis. The plasmid with correct sequence was named pFastbacHT B-RBD-HA.
[0061] Example 3: Rescue of recombinant baculovirus
[0062] The recombinant transfer vector pFastbacHT B-RBD-HA was used to transform DH10Bac competent cells, which were cultured at 37 ℃ in the dark for 48 h, then blue-white spot screening was performed, and the white spot was picked and cultured in the dark to extract the recombinant bacmid.
[0063] The recombinant bacmid was identified by PCR, and the upstream identification primer was as shown in SEQ ID NO: 10, and the downstream identification primer was as shown in SEQ ID NO: 11. The PCR reaction system was as follows: Phanta Max Super Fidelity DNA polymerase 1 μL, 2×Phanta Max Buffer 25 μL, dNTP Mix 1 μL, 1 μL of each of the upstream and downstream primers, 1 μL of diluted template, and ddH2O to 50 μL.
[0064] Reaction conditions: 94 ℃ pre-denaturation for 4 min; 94 ℃ denaturation for 45 s, 55 ℃ annealing for 4 min, 72 ℃ extension for 5 min, 35 cycles; 72 ℃ total extension for 7 min. The PCR identification result of the recombinant bacmid is shown in Figure 3 The correct recombinant bacmid was named rBacmid-RBD-HA.
[0065] The rBacmid-RBD-HA was transfected into Sf9 cells in the logarithmic growth phase, and the brief process was as follows:
[0066] (1) The Sf9 cells in good growth state were inoculated into a six-well plate at a density of 70% to 90%, and were placed in a biochemical incubator at 27 to 28 ℃ for 1 to 2 h to adhere.
[0067] (2) For each well of cells to be transfected, two sterile centrifuge tubes are prepared, each containing 100 μL of Sf-900 II SFM insect cell culture medium without serum and antibiotics to dilute the rBac and transfection reagent. One tube is added with 16 μg of rBac and mixed gently by pipetting; the other tube is added with 8 μL of LipoInsect transfection reagent and mixed gently by pipetting or vortexing. The diluted rBac and transfection reagent are allowed to stand at room temperature for about 2-5 minutes, and then the rBac solution is slowly added to the LipoInsect solution, and the centrifuge tube is gently inverted or mixed by pipetting, and allowed to stand for 15-30 minutes.
[0068] (3) The transfection mixture is added to the cells in the six-well plate at a volume of 200 μL per well, and mixed gently.
[0069] (4) The six-well plate is incubated in a 27-28 °C biochemical incubator for 4 hours, and then fresh complete medium is added and the cells are cultured for about 96 hours.
[0070] (5) The culture medium is collected from each well, centrifuged at 500 g for 5 minutes, and the supernatant is the first generation of recombinant baculovirus.
[0071] Example 4: Amplification and titration of recombinant baculovirus
[0072] The collected first generation of recombinant baculovirus is used to infect logarithmically growing suspension Sf9 cells at a volume ratio of 1:10, and the cells are cultured in a 27-28 °C biochemical incubator for 72 hours. The cell culture medium is centrifuged at 500 g for 5 minutes to remove large cell debris, and the collected supernatant is the second generation of recombinant baculovirus. The third generation of recombinant baculovirus is obtained in the same way.
[0073] The third generation of recombinant baculovirus is titrated using an immunofluorescence (IFA) experiment, as follows:
[0074] (1) Sf9 cells in the logarithmic growth phase are inoculated into a 96-well plate at a density of 70%-90%, and allowed to stand in a 27-28 °C biochemical incubator for 1-2 hours to adhere to the wall.
[0075] (2) The third generation of recombinant baculovirus is diluted in a centrifuge tube at a 10-fold dilution ratio, and diluted to 10 -10 .
[0076] (3) The original culture medium is discarded, and the diluted virus solution is added to the 96-well plate, with 8 replicates for each dilution, and positive and negative controls are also set.
[0077] (4) Infection for 1 h in 27~28 ℃ biochemical culture, shake the cell plate every 15 min to make the virus fully contact with the cells. After the end, add the culture medium and put it in 27~28 ℃ biochemical culture for 6 days.
[0078] (5) Take out the cell plate and discard the culture medium, add 4 % polyformaldehyde, and fix it at room temperature for 15 min.
[0079] (6) Wash the cell plate with PBST for 3 times, 5 min each time.
[0080] (7) Add Triton-X 100 permeabilization treatment for 10 min.
[0081] (8) Wash the cell plate with PBST for 3 times, 5 min each time.
[0082] (9) Block with 2 % (w / v, g / 100 ml) skim milk for 30 min, and wash the cell plate with PBST for 3 times, 5 min each time.
[0083] (10) Add mouse anti-His tag primary antibody, incubate overnight at 4 ℃. Wash the cell plate with PBST for 3 times, 5 min each time.
[0084] (11) Add goat anti-mouse FITC conjugated fluorescent secondary antibody, incubate for 45 min at room temperature in the dark. Wash the cell plate with PBST for 3 times, 5 min each time.
[0085] (12) Observe with an inverted fluorescence microscope, and calculate the virus titer by Reed-Muench method. The virus titer of the third generation of recombinant baculovirus is 1.5×10 8 PFU / mL.
[0086] Example 5: Expression of recombinant protein and verification of optimal expression conditions
[0087] Sf9 cells in logarithmic growth phase were inoculated into a six-well plate at a density of 70 % ~ 90 %. Sf9 cells were infected with P3 generation recombinant baculovirus at an MOI of 1. Place in 27~28 ℃ biochemical culture for 1 h, shake the cell plate every 15 min to make the virus fully contact with the cells. Add complete culture medium and put it in 27~28 ℃ biochemical culture for 72 h. Identify the expression of recombinant protein by Western blot method. The operation method of Western blot is as follows:
[0088] (1) Discard the culture medium, add 200 μL NP40 in the six-well plate, and gently blow the cells to transfer them to a 1.5 mL centrifuge tube, and put it in a homogenizer to fully lyse the cells.
[0089] (2) Take 40 μL of recombinant protein sample, add 10 μL of 5xLoading buffer, mix, boil in a water bath for 5 min, centrifuge at 12000 g for 1 min, and take 8 μL of supernatant for polyacrylamide gel electrophoresis.
[0090] (3) After electrophoresis, take a nitrocellulose membrane of appropriate size, assemble according to the arrangement of "negative electrode-filter paper-gel-membrane-filter paper-positive electrode", place in the membrane transfer instrument, set 0.4 A, and transfer the membrane for 35 min.
[0091] (4) After the transfer is completed, take out the membrane and block with 5% skimmed milk for 1 h. After blocking is completed, wash the membrane with PBST solution three times, each for 5 min.
[0092] (5) Add mouse anti-His tag primary antibody, incubate on a shaker at 4°C overnight. After incubation is completed, wash the membrane with PBST solution three times, each for 5 min.
[0093] (6) Add goat anti-mouse HRP conjugated secondary antibody, incubate on a shaker at room temperature for 1 h. After incubation is completed, wash the membrane with PBST solution three times, each for 5 min.
[0094] (7) Mix ECL developing solution A and B at a ratio of 1:1. Add the mixed solution to the membrane, and expose it to a chemiluminescence imager.
[0095] Verify the effects of MOI and sampling time of recombinant baculovirus on expression of recombinant protein.
[0096] Infect Sf9 cells with P3 generation recombinant baculovirus at a ratio of MOI = 1-5, collect samples after 72 h, and identify the expression of recombinant protein by Western blot method to verify the effect of inoculation MOI on expression of recombinant protein. The expression amount of recombinant protein is the highest when MOI = 5.
[0097] Infect Sf9 cells with P3 generation recombinant baculovirus at a ratio of MOI = 1, collect samples at 24 h, 48 h, 72 h, 96 h, and 120 h, respectively, and identify the expression of recombinant protein by Western blot method to verify the effect of sampling time on expression of recombinant protein. The protein expression amount is the highest when the sampling time is 96 h after infection (as shown in Figure 4 ).
[0098] Example 6: Purification and identification of recombinant protein
[0099] Purify the recombinant protein by nickel ion affinity chromatography column. The specific experimental steps are as follows:
[0100] (1) Put the gravity column containing nickel ion filler on the iron stand, remove the lower plug end and the upper plug end in turn, and dry the protective liquid of the gravity column.
[0101] (2) Add five column volumes of Lysis Buffer to the column tube, and balance to make the filler in the same buffer system as the target protein, which plays a protective role for the protein.
[0102] (3) Add the sample to the balanced gravity column, and the sample retention time is at least 2 min to ensure that the target protein is in full contact with the medium and improve the recovery rate of the target protein. Collect the flow-through liquid for subsequent SDS-PAGE analysis.
[0103] (4) Wash with 10-15 times the volume of Wash Buffer to remove non-specifically adsorbed impurities. Collect the wash liquid for subsequent SDS-PAGE analysis.
[0104] (5) Use 5-10 times the column volume of Elution Buffer to elute the target protein, and slowly collect the eluate.
[0105] (6) Use 3 times the column volume of Lysis Buffer and 5 times the column volume of deionized water to balance the filler. Store the gravity column in an equal volume of 20% ethanol at 2-8°C to prevent bacterial contamination of the filler.
[0106] Analyze the flow-through liquid, wash liquid and eluate by SDS-PAGE, and the experimental steps are as follows:
[0107] (1) Take 40 μL of flow-through liquid, wash liquid and eluate sample, add 10 μL of 5xLoading buffer, mix well, boil in a water bath for 5 min, centrifuge at 12000 g for 1 min, and take 8 μL of supernatant for polyacrylamide gel electrophoresis.
[0108] (2) After electrophoresis, put the gel into Coomassie brilliant blue and boil, and put it on a shaker at 55 r / min for 30 min.
[0109] (3) Take out the gel, put it into the destaining solution and boil, and put it on a shaker at 55 r / min overnight for destaining. Observe the protein purification the next day. The purification effect of the nickel ion chromatography column on the recombinant protein is shown in Figure 5 .
[0110] The protein solution was concentrated using an ultrafiltration tube, with the final volume not exceeding 5% of the size-exclusion column volume. Centrifugation at 14400 g for 2 min at 4 °C removed microbubbles. Further purification of the target protein was performed using molecular sieve chromatography on a Superdex 20010 / 300 GL (GE) column. The molecular sieve chromatography buffer consisted of 20 mM Tris (pH 8.0) and 150 mM NaCl. After molecular sieve chromatography, the collected samples were analyzed by non-denaturing gel electrophoresis. The results are shown below. Figure 6 As shown, the recombinant protein has only one main peak around the elution volume of 9 mL, and the protein band is above 250 kDa.
[0111] Take 3–10 μL of the purified recombinant protein sample and drop it onto a copper grid, ensuring a coverage area of ≥80%. Let it stand for 3–8 min, then aspirate excess liquid with an absorbent strip. Add 3–10 μL of 2% phosphotungstic acid staining solution to the copper grid, let it stand for 3–5 min, then aspirate excess liquid. Repeat this staining process by adding the solution a second time. Irradiate the stained copper grid under a light for 1–3 min until it dries, then observe it under a transmission electron microscope. Figure 6 As shown, the recombinant protein has a bouquet-like trimer structure with a length of 15-20 nm.
[0112] Example 7: Immunogenicity test of recombinant protein vaccine against H9N2 subtype avian influenza
[0113] The purified recombinant protein was mixed with MONTANIDE at a ratio of 1:2 (v / v). TM The vaccine was prepared using ISA 71R VG adjuvant. The immunization groupings and dosages for each group are shown in Table 1. Blank cells indicate "none". Each group consisted of 11 SPF chickens. The immunization challenge plan is as follows: Figure 7 As shown, SPF chickens were initially immunized at 7-10 days of age, followed by a booster immunization two weeks later. Three weeks after the initial immunization, they were challenged with the virus via eye drops or nasal drops. Serum samples were collected every 7 days after the initial immunization to detect neutralizing antibody levels. Pharyngeal and cloacal swabs were collected on days 3, 5, 7, and 9 post-challenge to detect virus shedding. Simultaneously, trachea and lungs were collected on day 7 post-challenge for pathological sectioning to observe histopathological changes.
[0114] Table 1. Experimental Design for Immunization with Recombinant Protein Vaccine and Challenge with H9N2 Subtype Avian Influenza Virus
[0115]
[0116] Neutralizing antibody levels were detected using a cellular neutralization assay for H9N2 subtype avian influenza virus in MDCK cells. The specific experimental procedure is as follows:
[0117] (1) Seed MDCK cells in the logarithmic growth phase into 96-well plates and start the experiment when the density is greater than 95%.
[0118] (2) The serum to be tested was placed in a 56 ℃ water bath for 30 min to inactivate it, and then serially diluted in a new 96-well plate at dilutions of 1:10, 1:20, 1:40, ..., 1:1280.
[0119] (3) Dilute the viral titer of H9N2 subtype avian influenza virus strains A / chicken / Anhui / LH99 / 2017 or A / chicken / Changzhou / 0102 / 2023 to 100 TCID. 50 50 μL was added to a 96-well plate. Cell positive control, serum positive control, and virus back-tipping group were also set up.
[0120] (4) Gently shake the mixture of virus and serum and incubate at 37 °C for 1 h.
[0121] (5) Discard the cell culture medium in the cell plate, transfer the mixture of virus and serum to MDCK cells, and place them in a 37 ℃ incubator with 5 % CO2 for virus infection for 1 h. During this period, shake the cell plate once every 15 min to disperse the virus evenly.
[0122] (6) Add cell maintenance medium without agarose and incubate in a 37°C incubator with 5% CO2 for 24-48 h.
[0123] (7) Cell infection status can be identified by IFA. A determination can be made when the virus back-split group, cell-positive control group, and serum-positive group are all valid. It can inhibit 100 TCID. 50 The highest serum dilution of virus-infected cells is the neutralizing titer in the cells.
[0124] The results are as follows Figure 8 As shown, the high-dose recombinant protein vaccine can induce high levels of neutralizing antibodies against the homologous H9N2 subtype avian influenza virus, with no significant difference compared to commercially available inactivated vaccines. Furthermore, the recombinant protein vaccine exhibits cross-immunogenicity against heterologous H9N2 subtype avian influenza viruses.
[0125] Example 8: Detection of the immunoprotective effect of recombinant protein vaccine against H9N2 subtype avian influenza
[0126] Pharyngeal and cloacal swabs were collected from chickens challenged with H9N2 subtype avian influenza virus on days 3, 5, 7, and 9 post-challenge. Virus shedding was detected using a hemagglutination assay, as detailed below:
[0127] (1) Put the swab into the centrifuge, 4 ℃, 6000 g centrifugation for 10 min.
[0128] (2) Take the supernatant bursa cavity and inoculate 9~11 day-old SPF chicken embryos, 0.2 mL per embryo, and repeat three embryos per sample. Place the embryos in 37 ℃ and incubate, and take out the dead embryos within 24 h every 12 h.
[0129] (3) After 120 h of culture, take out the chicken embryos and collect the bursa fluid for hemagglutination detection. If at least one of the three repeats of the same sample has a hemagglutination titer ≥ 4log2, it is determined to be positive for detoxification.
[0130] The detoxification levels of the homologous H9N2 subtype avian influenza virus are shown in Table 1, and the detoxification levels of the heterologous H9N2 subtype avian influenza virus are shown in Table 2. Figure 9 Figure 10 The detoxification levels of the throat and cloaca of the immunized SPF chickens after challenge are significantly reduced.
[0131] Observe the pathological sections to judge the damage of the virus to the corresponding tissues and organs, and the specific operation is as follows:
[0132] Soak the collected trachea and lung tissues in 3~5 times the volume of 4 % paraformaldehyde, and fix at room temperature for 48 h. After the fixed sample is treated regularly, embed it in paraffin, cut into 5 um thin sections, and perform HE staining. Then observe the pathological sections using a section scanner.
[0133] The histopathological changes after challenge of the homologous H9N2 subtype avian influenza virus are shown in Table 3, and the histopathological changes after challenge of the heterologous H9N2 subtype avian influenza virus are shown in Table 4. Figure 11 Figure 12 Compared with the 100 μg immunized SPF chickens, the tracheal mucosa of the PBS group SPF chickens is significantly thickened, and the lung has a large number of inflammatory cell infiltration and bleeding. It is proved that the recombinant protein vaccine has good cross-protection effect on the H9N2 subtype avian influenza virus, reduces the virus shedding and the damage of the corresponding tissues and organs.
[0134] Example 9: Immunogenicity detection of the recombinant protein vaccine on QX subtype avian infectious bronchitis
[0135] The immunization grouping and the immunization amount of each group are shown in Table 2, and the blank part represents "none". Each group has 11 SPF chickens. The immunization and challenge plan is shown in Table 5. Figure 13 The SPF chickens were immunized at 7-10 days old, and boosted 2 weeks later. The chickens were challenged 3 weeks after the initial immunization. The sera were collected every 7 days after the initial immunization for detecting the level of neutralizing antibodies. The pharyngeal and cloacal swabs were collected at 7 and 12 days after the challenge for detecting the virus shedding. The trachea, lung and kidney were collected at 7 and 12 days after the challenge for detecting the virus load in the tissues. The trachea was collected at 7 days after the challenge for observing the histopathological changes and the tracheal cilia score.
[0136] Table 2. Design of the experiment of the recombinant protein vaccine immunization and QX IBV challenge
[0137]
[0138] The level of specific antibodies after the immunization was detected by ELISA, and the specific operation was as follows:
[0139] The serum samples collected at 7, 14 and 21 days after the initial immunization were inactivated at 56 °C for 30 min. The level of IBV-specific IgG antibodies was determined by indirect ELISA. First, the serum samples were diluted 100 times in PBS buffer, and then detected using a commercial IBV antibody detection kit (IDEXX, Westbrook, MA, USA) according to the instructions. Each sample was diluted in triplicate, and the sample / positive (S / P) ratio was calculated using the following formula: [(sample mean - negative mean) / (positive mean - negative mean)]. The S / P ratio greater than 0.2 was considered to be IBV antibody positive.
[0140] The results are shown in Figure 14 As shown, the ability of the recombinant protein vaccine to induce IBV-specific antibodies was enhanced with the increase of the immunization dose. Among them, the high-dose recombinant protein vaccine of 100 μg could induce a higher level of specific antibody production, and the difference with the commercial attenuated vaccine was minimal (*, P<0.05).
[0141] The level of neutralizing antibodies was detected by the chicken embryo neutralization experiment of QX IBV using 9-11-day-old SPF chicken embryos. The specific experimental operation was as follows:
[0142] The serum samples collected at 21 days after the initial immunization were inactivated at 56 °C for 30 min, and then serially diluted twice with PBS. Meanwhile, the virus was diluted to 200 EID 50The diluted serum was mixed with an equal volume of diluted virus liquid, incubated at 37 ℃ for 1 h, and then 0.2 mL of the mixture was inoculated into the allantoic cavity of a 9-day-old SPF chicken embryo. After 6 days, the embryo development was observed and counted, and the neutralization titers of the virus for each serum sample were calculated by the Reed and Muench method.
[0143] The results are shown in Table 2. Figure 15 As shown in Table 2, a high level of neutralizing antibody production can be induced after immunization with a high dose of 100 μg of the recombinant protein vaccine, which proves that the recombinant protein vaccine has good immunogenicity against QX subtype avian infectious bronchitis virus.
[0144] Example 10: Detection of the immune protection effect of the recombinant protein vaccine against QX subtype avian infectious bronchitis
[0145] On the 7th and 12th days after the challenge, the pharyngeal swabs and cloacal swabs of the challenged chickens were collected, and RT-qPCR was used for virus detection, with the following specific operations:
[0146] (1) The swabs were placed in a centrifuge, centrifuged at 6000 g for 10 min at 4 ℃.
[0147] (2) A 1.5 mL centrifuge tube was taken, 500 μL of the supernatant of the swab was added, and an equal volume of Trizol was added, which was repeatedly blown to lyse, and was placed on ice.
[0148] (3) One-fifth volume of chloroform was added to the lysate, and it was vigorously shaken for 15 s. After the system became a milky emulsion, it was placed on ice for 5 min.
[0149] (4) Centrifugation was performed at 12000 g for 15 min at 4 ℃, at which time the solution was divided into three layers, and the upper aqueous phase was taken to a new centrifuge tube. An equal volume of pre-cooled isopropanol was added, and it was mixed well by inverting. It was placed in a -20 ℃ refrigerator for 15 min.
[0150] (5) Centrifugation was performed at 12000 g for 10 min at 4 ℃, and the supernatant was discarded. 1 mL of 75 % ethanol was added, and the precipitate was resuspended and inverted several times. It was placed at room temperature for 3-5 min.
[0151] (6) Centrifugation was performed at 12000 g for 5 min at 4 ℃, and the supernatant was discarded. The centrifuge tube was dried for 2-5 min, 20 μL of DEPC water was added for dissolution, and the concentration was determined.
[0152] (7) The extracted RNA was used as a template to generate the corresponding cDNA using the HiScript II 1st Strand cDNA Synthesis Kit and random primers.
[0153] (8) A pair of qPCR detection primers were designed using the conserved region of IBV N protein: IBV-F (TGGGCGTGTTACAGCAATGCTCA), IBV-R (TTGGGCGTGTGCCTACACCA). The standard curve was y = -3.3154x + 37.704 (R2= 0.9991).
[0154] (9) All samples were prepared in triplicate under light-free conditions with the following qPCR system: 2 x qPCR Mix 10 μL, 0.4 μL of each upstream and downstream primer, 2 μL of cDNA, and ddH2O to make up to 20 μL. Fluorescent quantitative PCR was performed in a Roche LightCycler 96, with the following specific program: 95 °C for 5 min, 95 °C for 10 s, 60 °C for 30 s, 40 cycles. The copy number of viral RNA was calculated according to the standard curve to evaluate the detoxification level.
[0155] The detoxification results of QX subtype avian infectious bronchitis virus are shown in Figure 16 On the 7th day after challenge, the detoxification levels of the larynx and cloaca of the 50 μg and 100 μg recombinant protein vaccine immunization groups were significantly higher than those of the commercial attenuated vaccine group (****, P < 0.0001; *, P < 0.05); on the 12th day after challenge, the detoxification levels of the larynx and cloaca of the 100 μg recombinant protein vaccine immunization group had no significant difference compared with the commercial attenuated vaccine, while the detoxification levels of the larynx and cloaca of the 50 μg recombinant protein vaccine immunization group also decreased compared with the commercial attenuated vaccine.
[0156] The immune protection effect of the recombinant protein vaccine on the trachea was further evaluated by tracheal cilia scoring. The specific operation is as follows:
[0157] On the 7th day after challenge, the trachea of the chicken was taken for tracheal cilia scoring. Briefly, 9 tracheal rings were taken from each chicken, from the upper, middle and lower parts of the trachea, with three tracheal rings from each part. They were placed in a 96-well plate containing 10 % (v / v) FBS in DMEM medium. The cilia activity was observed under a low-power microscope, and each tracheal ring was scored according to the following criteria: 0 points for 100 % of the tracheal cilia moving; 1 point for 75 % to 100 % of the tracheal cilia moving; 2 points for 50 % to 75 % of the tracheal cilia moving; 3 points for 25 % to 50 % of the tracheal cilia moving; 4 points for 0 % to 25 % of the tracheal cilia moving. The tracheal cilia score of each group was calculated according to the above criteria.
[0158] The results are shown in Figure 17As shown in the figure, the tracheal cilia scores of the recombinant protein vaccine immunization groups were about 1.8 and 0.6 under two immunization doses. The tracheal cilia damage score of the 100 μg recombinant protein vaccine immunization group was the lowest, and there was no significant difference compared with the commercial vaccine group.
[0159] The trachea, lung and kidney at the 7th and 12th days after challenge were collected, and the viral load in the tissues was detected by RT-qPCR after fully grinding by a tissue grinder.
[0160] The results are shown in the figure Figure 18 As shown in the figure, the viral loads in the trachea and lung of the recombinant protein vaccine immunization group at the 7th day after challenge were higher than those of the commercial attenuated vaccine group, and the difference between the 100 μg recombinant protein vaccine immunization group and the commercial attenuated vaccine group was the lowest (*, P<0.05), and the viral load in the kidney of the 100 μg recombinant protein vaccine immunization group had no significant difference with the commercial attenuated vaccine; at the 12th day after challenge, the viral loads in the trachea, lung and kidney of the 100 μg recombinant protein vaccine immunization group had no significant difference with the commercial attenuated vaccine, and the viral loads in the trachea, lung and kidney of the 50 μg recombinant protein vaccine immunization group also decreased compared with the commercial vaccine group (*, P<0.05).
[0161] The damage of virus to the corresponding tissues and organs was observed and judged by pathological section.
[0162] The results are shown in the figure Figure 19 As shown in the figure, the PBS group had the most serious pathological changes in the trachea, lung and kidney, which were manifested as tracheal cilia shedding, tracheal mucosa thickening, lung inflammatory cell infiltration and hemorrhage, and kidney glomerular atrophy; the 50 μg recombinant protein vaccine immunization group had tracheal mucosa thickening, a small amount of tracheal cilia shedding, and no obvious pathological changes in the lung and kidney; the 100 μg recombinant protein vaccine immunization group and the commercial vaccine group had almost no obvious pathological changes in the trachea, lung and kidney. The above results show that the recombinant protein vaccine has good immune protection effect on QX subtype avian infectious bronchitis virus, and can significantly reduce the virus discharge, replication and damage to the tissues and organs.
[0163] The protection content of the present application is not limited to the above examples. Changes and advantages that can be thought of by those skilled in the art without departing from the spirit and scope of the present application are included in the present application, and the appended claims are protected.
[0164] Sequence listing
[0165] SEQ ID NO: 1
[0166] FDSAKNYVYYYQSAFRPTNGWHLQGGAYAVVNSTNYTSNAGSASGCTVGIIRDVYNQSAASIAMTAPPQGMAWSKSQFCSAHCNFSEITVFVTHCYSSGAGSCPITGMIARDHIRISAMKNGSLFYNLTVSVSKYSRFKSFQCVNNLTSVYLNGDLVFTSNKTTDVTSAGVYFKAGGPVNYSVMKEFKVLAYFVNGTAQDVILCDNSPKGLLACQYSTGNFSDGFYPFTNSTLVRDKFIVYRESSVNTTLTLTNFTF
[0167] SEQ ID NO: 2
[0168] ATSLGHPLILDTCTIEGLIYGNPSCDPLLGGREWSYIVERPSAVNGLCYPGNVENLEELRSLFSSSRSYQRIQIFPDTIWNVSYSGTSKACSDSFYRSMRWLTQKNNAYPTQDAQYTNNQGKNILFMWGINHPPTDTTQTNLYTRTDTTTSVATEEMNRIFKPLIGPRPLVNGLMGRINYYWSVLKPGQTLRIKSDGNLIAPWYGHILSGESHGRILKTDLKRGS
[0169] SEQ ID NO: 3
[0170] MLLVNQSHQGFNKEHTSKMVSAIVLYVLLAAAAHSAFA
[0171] SEQ ID NO: 4
[0172] METISLITILVVATVSNA
[0173] SEQ ID NO: 5
[0174] RLNMINNKVDDQIQ
[0175] SEQ ID NO: 6
[0176] MLLVNQSHQGFNKEHTSKMVSAIVLYVLLAAAAHSAFADKICIGYQSTNSTETVDTLTEN NVPVTHAKELLHTEHNGMLCGGGGFDSAKNYVYYYQSAFRPTNGWHLQGGAYAVVNS TNYSNAGSASGCTVGIIRDVYNQSAASIAMTAPPQGMAWSKSQFCSAHCNFSEITVF VTHCYSSGAGSCPITGMIARDHIRISAMKNGSLFYNLTVSVSKYSRFKSFQCVNNLT SVYLNGDLVFTSNKTTDVTSAGVYFKAGGPVNYSVMKEFKVLAYFVNGTAQDVILCD NSPKGLLACQYSTGNFSDGFYPFTNSTLVRDKFIVYRESSVNTTLTNFTFGGGGCTV QCQTEKGGLNTTLPFQNVSKYAFGNCSKYIGVKSLKLAVGLRNVPSRSSRGLFGAIAG FIEGGWSGLVAGWYGFQHSNDQGVGMAADRDSTQKAIDKITSKVNNIVDKMNKQYE IIDHEFSEVETCMKQIEDKIEEIESKDIWAYNAELLVLLENQKTLDEHDANVNNLYN KVKRALGSNAVEDGKGCFELYHKCDDHCMETIRNGTYNRRKYQEESKLERQKIEGV KLESEETYKILTYIPEAPRDGQAYVRKDGEWVLLSTFLGSAHHHHHH
[0177] SEQ ID NO: 7
[0178]
[0179] SEQ ID NO: 8
[0180] TTTCAGGGCGCCATGGGATCCATGCTATTGGTCAATCAGAGC
[0181] SEQ ID NO: 9
[0182] CTTGGTACCGCATGCCTCGAGTCAATGATGATGGTGATGAT
[0183] SEQ ID NO: 10
[0184] GTTTTCCCAGTCACGAC
[0185] SEQ ID NO: 11
[0186] CAGGAAACAGCTATGAC
[0187] SEQ ID NO: 12
[0188] METISLITILVVATVSNADKICIGYQSTNSTETVDTLTENNVPVTHAKELLHTEHNGMLCATSLGHPLILDTCTIEGLIYGNPSCDPLLGGREWSYIVERPSAVNGLCYPGNVENLEELRSLFSSSRSYQRIQIFPDTIWNVSYSGTSKACSDSFYRSMRWLTQKNNAYPTQDAQYTNNQGKNILFMWGINHPPTDTTQTNLYTRTDTTTSVATEEMNRIFKPLIGPRPLVNGLMGRINYYWSVLKPGQTLRIKSDGNLIAPWYGHILSGESHGRILKTDLKRGSCTVQCQTEKGGLNTTLPFQNVSKYAFGNCSKYIGVKSLKLAVGLRNVPSRSSRGLFGAIAGFIEGGWSGLVAGWYGFQHSNDQGVGMAADRDSTQKAIDKITSKVNNIVDKMNKQYEIIDHEFSEVETRLNMINNKVDDQIQDIWAYNAELLVLLENQKTLDEHDANVNNLYNKVKRALGSNAVEDGKGCFELYHKCDDHCMETIRNGTYNRRKYQEESKLERQKIEGVKLESEETYKILTIYSTVASSLVIAMGFAAFLFWAMSNGSCRCNICI
[0189] SEQ ID NO: 13
[0190] TGGGCGTGTTACAGCAATGCTCA
[0191] SEQ ID NO: 14
[0192] TTGGGCGTGTGCCTACACCA.
Claims
1. A recombinant protein, characterized in that, The recombinant protein is a chimeric protein constructed by replacing the head domain of the avian influenza virus HA protein with the RBD domain of the avian infectious bronchitis virus S protein; the amino acid sequence of the recombinant protein is shown as SEQ ID NO:
6.
2. A nucleic acid molecule encoding the recombinant protein of claim 1, characterized in that, The nucleotide sequence of the nucleic acid molecule is shown as SEQ ID NO:
7.
3. Biomaterial comprising the nucleic acid molecule of claim 2, characterized in that, The biological material is an expression cassette, a recombinant vector or a recombinant microorganism.
4. A method for preparing the recombinant protein according to claim 1, characterized by, The method comprises the following steps: (1) Gene cloning: homologous recombination primers shown as SEQ ID NO: 8 and SEQ ID NO: 9 are designed according to the nucleotide sequence of the recombinant protein and the pFastbacHT B vector, PCR amplification is performed, and the amplification product is connected with the linearized pFastbacHTB vector, transformed to obtain a recombinant transfer vector; (2) Recombinant bacmid preparation: the recombinant transfer vector is transformed into DH10Bac E. coli competent cells to obtain a recombinant bacmid; (3) Virus rescue and amplification: the recombinant bacmid is used to transfect insect cells, a recombinant baculovirus is rescued, and amplification and titration are performed; (4) Protein expression: the insect cells are infected with the amplified recombinant baculovirus, and the cells are harvested 96 hours after infection; (5) Protein purification: the harvested cells are lysed, concentrated by centrifugation, and purified using a nickel ion affinity chromatography column to obtain the recombinant protein.
5. A vaccine comprising a polynucleotide of claim 1. The vaccine comprises the recombinant protein as claimed in claim 1 as an immunogenic component, and a pharmaceutically acceptable adjuvant.
6. Use of the recombinant protein as claimed in claim 1 in the preparation of a vaccine or a medicament for preventing H9N2 subtype avian influenza and QX subtype avian infectious bronchitis in poultry.
7. Use of the vaccine as claimed in claim 5 in the preparation of a medicament for preventing H9N2 subtype avian influenza and QX subtype avian infectious bronchitis in poultry.
Citation Information
Patent Citations
Avian influenza and infectious bronchitis hybrid virus-like particle as well as preparation method and application thereof
CN102373184A
H9N2 subtype avian influenza virus mRNA vaccine as well as preparation method and application thereof
CN115252770A
Beta-coronavirus and influenza chimeric antigen as well as preparation method and application thereof
CN116514991A
Influenza virus and coronavirus combined vaccine based on mRNA (messenger ribonucleic acid) and preparation method thereof
CN118497235A
Influenza A virus-like particle for chimeric expression of novel coronavirus RBD protein as well as preparation method and application of influenza A virus-like particle
CN120683135A
